Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.

Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.

Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.

Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.

Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.

Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.

FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.

How past “untreatable” labels mislead psychiatry—and why measurement-informed care and difficult-to-treat depression replace today’s treatment-resistant mindset.